Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

China flag China · Delayed Price · Currency is CNY
56.46
+1.28 (2.32%)
Jun 17, 2026, 1:00 PM CST
Market Cap34.11B +40.5%
Revenue (ttm)4.32B +248.9%
Net Income2.97B +315.2%
EPS4.78 +312.5%
Shares Out 618.09M
PE Ratio11.53
Forward PE53.06
Dividend0.48 (0.86%)
Ex-Dividend DateJun 18, 2026
Volume3,318,048
Open55.50
Previous Close55.18
Day's Range54.81 - 56.70
52-Week Range46.78 - 96.60
Beta0.31
AnalystsBuy
Price Target89.17 (+57.94%)
Earnings DateAug 21, 2026

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include Enbrel, a recombinant human type II tumor necrosis factor receptor-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation; and Enbrel, an anti-IL-17A humanized monoclonal antibody ambroxol injection for t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 1,012
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688336
Full Company Profile

Financial Performance

In 2025, SHA:688336's revenue was 4.20 billion, an increase of 251.81% compared to the previous year's 1.19 billion. Earnings were 2.90 billion, an increase of 311.49%.

Financial Statements